IP Library Granted Patent US 8,178,121
Granted Patent B2
US 8,178,121 · App. 10/492,648 · Granted May 15, 2012

Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent

Assignees: Baxter International Inc.; Baxter Healthcare S.A.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,178,121
App. No.
10/492,648
Granted
May 15, 2012
Kind
B2
Abstract

The present invention refers to ready-to-use highly stable paracetamol injectable solutions, prepared by mixing paracetamol, water, propylene glycol, and a citrate buffer. (pH 4.5 to 6.5), and by heating said solution under preset conditions. The resulting solution may be stored for an extended period of time within a wide range of temperatures, with no paracetamol precipitation and/or its chemical modification.

Claims (10)

1. A process for the preparation of a packaged, ready-to-use paracetamol injectable solution, the process comprising: mixing paracetamol with water, propylene glycol as the only co-solvent, and a citrate buffer (pH from 4.5 to 6.5), heating said solution to a temperature between 70° C. and 130° C., keeping same at said temperature for 10 min at least, wherein the heating to between 70° C. and 130° C. is followed by a packaging step, and the packaging step is followed by a sterilization step.

2. The process according to claim 1 , wherein paracetamol is added in such a quantity as to secure a concentration lower than or equal to 4% by weight.

3. The process according to claim 1 , wherein propylene glycol is added in such a quantity as to secure a final concentration of 0.1% to 40% w/v.

4. The process according to claim 3 , wherein propylene glycol is added in such a quantity as to secure a final concentration of 0.5% to 20% w/v.

5. The process according to claim 4 , wherein propylene glycol is added in such a quantity as to secure a final concentration of 0.5% to 10% w/v.

6. The process according to claim 5 , wherein propylene glycol is added in such a quantity as to secure a final concentration of 0.7% to 3% w/v.

7. The process according to claim 1 , wherein the pH of said citrate buffer is in the range from 5 to 6.

8. The process according to claim 7 , wherein said citrate buffer consists of citric acid and disodium monohydrogen phosphate.

9. The process according to claim 1 , wherein said solution is filled into injection phials or bottles or perfusion bags.

10. A method to enhance the stability of paracetamol liquid pharmaceutical compositions, characterized in that paracetamol is formulated by mixing paracetamol with water, propylene glycol as the only co-solvent, and a citrate buffer (pH from 4.5 to 6.5), heating said solution to a temperature between 70° C. and 130° C., keeping same at said temperature for 10 min at least, wherein the heating to between 70° C. and 130° C. is followed by a packaging step, and the packaging step is followed by a sterilization step.

Assignments (5)
CHANGE OF ADDRESS Recorded Apr 11, 2012
From: BAXTER HEALTHCARE S.A.
To: BAXTER HEALTHCARE S.A.
Reel/Frame 028030/0685 →
MERGER Recorded May 11, 2010
From: BIOREN S.A.
To: BIGMAR-BIOREN PHARMACEUTICALS S.A.
Reel/Frame 024364/0421 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2010
From: SINTETICA S.A.
To: BAXTER HEALTHCARE S.A.; BAXTER INTERNATIONAL INC.
Reel/Frame 024364/0441 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2010
From: BIGMAR-BIOREN PHARMACEUTICALS S.A.
To: SINTETICA S.A.
Reel/Frame 024364/0456 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2004
From: NGUYEN-XUAN, THO
To: BIOREN S.A.
Reel/Frame 015671/0155 →
Priority Claims (1)
IT MI2001A2135 · Oct 16, 2001 · national
Continuity (1)
Related Publication 20040247627A1 · Dec 9, 2004